Utah Clinical Trials Report — June 2026

For Utah residents considering participation in clinical research, June 2026 presents a critical window of opportunity for trials nearing their conclusion, alongside an array of promising new studies. Across the state, 67 clinical trials are scheduled to close within the next 90 days, meaning time is running out to enroll. This includes 4 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various heart conditions, mental health, and cancer are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder
• Aortic valve insufficiency
• Heart failure
• Aortic regurgitation
• Solid tumors
• Aortic insufficiency
• Advanced breast cancer
• Astrocytoma
• Arthroplasty total hip replacement
• Acute lymphoblastic leukemia

Significant New Research Initiatives Launch Across Utah

This month, Utah welcomes 21 new clinical trials, a slight decrease from the 26 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine, as well as crucial vaccine development.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 study titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants, evaluating a new treatment for weight management. They are also leading NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," a Phase 3 trial targeting 1,100 participants to assess aleniglipron's efficacy and safety in individuals with both conditions.
• AstraZeneca is sponsoring two important Phase 3 trials for type 2 diabetes mellitus. NCT07662109 investigates "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus," planning for 2,000 participants. Additionally, NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," will enroll 1,200 participants to compare elecoglipron with an existing treatment.
• Pfizer is leading two important Phase 3 vaccine trials. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children.
• Individuals experiencing migraines may be interested in two Phase 3 trials sponsored by Kallyope Inc.: NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,800 participants, and NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," which plans for 1,000 participants.

Expanding Research Horizons: Conditions and Interventions

The 21 new trials opening this month in Utah cover a diverse range of health conditions, with a strong focus on metabolic health, infectious disease prevention, and neurological conditions. The most common conditions addressed by these new studies include:

• Type 2 diabetes mellitus (3 trials)
• Obesity (2 trials)
• Pneumococcal disease (2 trials)
• Overweight (2 trials)
• Migraine (2 trials)
• Chronic weight management (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 12 of the new studies. Biological treatments and behavioral interventions are also well-represented with 3 new trials each, alongside other types of research including devices, combination products, and dietary supplements.

Geographic Reach: Salt Lake City Leads, Opportunities Statewide

Utah's clinical research landscape continues to be robust, with 1,183 clinical trials currently recruiting across 44 cities and 518 research sites statewide. This month, the majority of new research initiatives are concentrated in the Salt Lake City metropolitan area, which saw 12 new trials open. However, opportunities are also expanding in other parts of the state:

• Bountiful (3 new trials)
• Ogden (3 new trials)
• Provo (3 new trials)
• St. George (2 new trials)
• Syracuse (2 new trials)
• Riverton (2 new trials)
• Draper (2 new trials)
• Layton (1 new trial)
• Pleasant Grove (1 new trial)

This distribution ensures that residents in various regions of Utah have access to cutting-edge research, even as Salt Lake City remains a central hub for clinical investigations.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 21 new trials launched this month, 5 are actively seeking healthy volunteers. Statewide, a total of 99 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Utah are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 3 include children as participants, and 16 include older adults, ensuring that research benefits diverse age groups. Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Utah sponsoring 3 of the new trials. Industry sponsors are also driving significant research efforts, with 16 new trials sponsored by pharmaceutical companies such as AstraZeneca, Pfizer, Kallyope Inc., and Gasherbrum Bio, Inc.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Utah.